Comparison Study of Two Rituximab Regimens in the Remission of ANCA Associated Vasculitis

Related Clinical Trial
PR3-AAV Resilient Remission or PRRR Study on Pharmacokinetics of Meperizumab Injection and NUCALA® in Healthy Male Volunteers Efficacy and Safety of Depemokimab Compared With Mepolizumab in Adults With Relapsing or Refractory Eosinophilic Granulomatosis With Polyangiitis (EGPA) Study of Mepolizumab-based Regimen Compared to Conventional Therapeutic Strategy in Patients With Eosinophilic Granulomatosis With Polyangiitis (E-merge) Comparison of Tofacitinib and Methotrexate in the Maintained Treatment of GPA Study of Salvage Therapy to Treat Patients With Granulomatosis With Polyangiitis Hydroxychloroquine in ANCA Vasculitis Evaluation Vasculitis Illness Perception (VIP) Study Reproductive Health in Men and Women With Vasculitis Low Dose Naltrexone to Improve Physical Health in Patients With Vasculitis Impact of Vasculitis on Employment and Income Induction of Regulatory t Cells by Low Dose il2 in Autoimmune and Inflammatory Diseases VCRC Tissue Repository Yellow Fever Vaccine in Patients With Rheumatic Diseases Journey of Patients With Vasculitis From First Symptom to Diagnosis One-Time DNA Study for Vasculitis Treatment of Necrotizing Vasculitides for Patients Older Than 65 Years Autologous Peripheral Blood Stem Cell Transplantation in Patients With Life Threatening Autoimmune Diseases Prevention of Glucocorticoid-Induced Osteoporosis in Rheumatic Diseases: Alendronate Versus Alfacalcidol. Clinical Transcriptomics in Systemic Vasculitis (CUTIS) The ANCA Vasculitis Questionnaire (AAV-PRO©) Vasculitis Pregnancy Registry VCRC Patient Contact Registry Patient-Reported Data Validation Study Educational Needs of Patients With Systemic Vasculitis Diagnostic Effectiveness of Virtual Bronchoscopy Alemtuzumab for ANCA Associated Refractory Vasculitis Interventional Cryotherapy for the Eradication of Benign Airway Disease (“ICE the BAD”) PRagmatic Analysis of Vitamin D in ANCA-Associated Vasculitis Cyclophosphamide Versus Methotrexate for Remission Maintenance in Systemic Necrotizing Vasculitides Plasma Exchange for Renal Vasculitis PRO Development for ANCA Associated Vasculitis BIANCA-SC: A Study of the Efficacy, Safety, and Tolerability of Blisibimod in Addition to Methotrexate During Induction of Remission in Subjects With ANCA-Associated Small Vessel Vasculitis RATTRAP: Infliximab Versus Rituximab in Systemic Necrotizing Vasculitides Pulse Versus Continuous Cyclophosphamide for Induction of Remission in ANCA-Associated Vasculitides Rituximab Vasculitis Maintenance Study Anti-Cytokine Therapy for Vasculitis Rituximab and Belimumab Combination Therapy in PR3 COMBIVAS American College of Rheumatology/European League Against Rheumatism (ACR/EULAR) Diagnostic and Classification Criteria for Primary Systemic Vasculitis Low-dose Glucocorticoid Vasculitis Induction Study Pilot Study of Short-Course Glucocorticoids and Rituximab for Treatment of ANCA-Associated Vasculitis Comparison Study of Two Rituximab Regimens in the Remission of ANCA Associated Vasculitis Rituximab for ANCA-associated Vasculitis (RAVE) Long-Term Follow-Up Study Evaluate the Remission MAINtenance Using Extended Administration of Prednisone in Systemic Anti-neutrophil Cytoplasmic Antibodies (ANCA)-Associated Vasculitis. The Assessment of Prednisone In Remission Trial (TAPIR) – Patient Centric Approach Steroids and Methotrexate to Treat Systemic Vasculitis Efficacy Study of Two Treatments in the Remission of Vasculitis Assessment of Lung Inflammation in Patients With Atopic Asthma Using Positron Emission Tomography The Assessment of Prednisone In Remission Trial – Centers of Excellence Approach Observation Study of Clinical Manifestation and Outcome in Chinese Patients With Pulmonary Vasculitis Abatacept for the Treatment of Relapsing, Non-Severe, Granulomatosis With Polyangiitis (Wegener’s) Rituximab for the Treatment of Wegener’s Granulomatosis and Microscopic Polyangiitis Cyclophosphamide and Prednisone Followed by Methotrexate To Treat Vasculitides Maintenance of Remission With Rituximab Versus Azathioprine for Newly-diagnosed or Relapsing Eosinophilic Granulomatosis With Polyangiitis. A Phase IIa Study of Intravenous Rituximab in Pediatric Participants With Severe Granulomatosis With Polyangiitis (Wegener’s) or Microscopic Polyangiitis Longitudinal Study for Eosinophilic Granulomatosis With Polyangiitis (Churg-Strauss) Longitudinal Protocol for Granulomatosis With Polyangiitis (Wegener’s) and Microscopic Polyangiitis Mycophenolate Mofetil for Treatment of Relapses of Wegener’s Disease or Microscopic Polyangiitis (MPA) Safety and Efficacy Study of IFX-1 in add-on to Standard of Care in Granulomatosis With Polyangiitis (GPA) and Microscopic Polyangiitis (MPA) Daclizumab to Treat Wegener’s Granulomatosis An Open Label Pilot Study Examining the Use of Rituximab in Patients With Wegener’s Granulomatosis Who Have Experienced Disease Relapse on Standard Therapies Etanercept to Treat Wegener’s Granulomatosis Treatment of Wegener’s Granulomatosis With Cyclophosphamide Mycophenolate Mofetil to Treat Wegener’s Granulomatosis and Related Vascular Inflammatory Conditions Phase I Trial of Recombinant Human Interleukin-10 (SCH 52000) in Patients With Wegener’s Granulomatosis Comparison of Treatments to Maintain Disease Remission in Patients With Wegener’s Granulomatosis and Related Vasculitis Syndromes Neutrophils as Prognostic Factors in Granulomatosis With Polyangiitis (Formerly Named Wegener’s Granulomatosis) Natural History of Granulomatosis With Polyangiitis: Clinical and Genetic Biomarkers of Airway Disease NoAAC PR-03 Study Analysis of Bronchial Tissue and Fluid in Patients With Wegener’s Granulomatosis TEMPO Study: Trimethoprim-Sulfamethoxazole in Granulomatosis With Polyangiitis Cardiovascular Involvement in Patients With Granulomatosis With Polyangiitis An Observational Study of The Safety of MabThera/Rituxan (Rituximab) in Participants With Granulomatosis With Polyangiitis (Wegener’s) or Microscopic Polyangiitis Study of One Protein Implicated in Wegener Disease Abatacept in Treating Adults With Mild Relapsing Wegener’s Granulomatosis Phase II Study on Gusperimus in Patients With Refractory Wegener’s Granulomatosis Etanercept for Wegener’s Granulomatosis Clinical Study Comparing the New Immunosuppressive Drug Gusperimus With the Conventional Treatment in Wegener’s Granulomatosis

Brief Title

Comparison Study of Two Rituximab Regimens in the Remission of ANCA Associated Vasculitis

Official Title

MAINtenance of Remission Using RITuximab in Systemic ANCA-associated Vasculitis II

Brief Summary

      The aim of this study is to assess the efficacy of a rituximab regimen based on rate of ANCA
      and CD19 lymphocytes for maintenance treatment in systemic ANCA-associated vasculitis:
      prospective, multicenter, controlled, randomized comparative study of two rituximab regimens:
      one based on ANCA and CD19 lymphocytes versus systematic infusions.

Detailed Description

      Randomized, controlled, national, multicenter, prospective study to compare systematic
      rituximab infusions (conventional therapy) to rituximab infusion based on rate of ANCA and
      CD19 lymphocytes in patients with systemic ANCA-associated vasculitis, in remission (achieved
      with an induction treatment combining corticosteroids and an immunosuppressant after the
      first flare of the disease (new diagnosis) or after a relapse. Patients will be stratified by
      first flare (66% of the patients) or relapse (33% of the patients). Patients complying with
      the inclusion criteria may be included when they are in remission from their vasculitis.
      Patients will be included at the time of remission and then randomized. They will receive
      maintenance treatment by 1)2 rituximab infusions mg at D1, D15 then every 6 months until
      month 18 (i.e. a total of 5 infusions), at the dose of 500 mg. 2) 1 rituximab infusion at the
      dose of 500 mg at D0 then ANCA status and CD19+ lymphocyte count will be monitored every 3
      months, and patients will receive new 500 mg rituximab infusions either if CD19 are > to
      0/mm3, or if ANCA are positive again or if ANCA titer significantly raises. After the 18
      month length of maintenance phase, i.e. after stopping immunosuppressive maintenance therapy,
      patients will be followed for an additional 10 month period. Patients with granulomatosis
      with polyangiitis will be prescribed cotrimoxazole 160/800 tid (for 2 additional years).

Study Phase

Phase 3

Study Type


Primary Outcome

Number of relapses

Secondary Outcome

 Number of patients with ANCA (Anti-Neutrophil Cytoplasmatic Antibodies)


Granulomatosis With Polyangiitis


Rituximab (Arm B)

Study Arms / Comparison Groups

 Rituximab infusion according biological parameters
Description:  Rituximab infusion based on ANCA and CD19 lymphocytes


* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.

Recruitment Information

Recruitment Status


Estimated Enrollment


Start Date

November 16, 2012

Completion Date

April 5, 2016

Primary Completion Date

April 5, 2016

Eligibility Criteria

        Inclusion Criteria:

          -  Granulomatosis with Polyangiitis Or microscopic polyangiitis complying Or
             kidney-limited disease With or without detectable ANCA (anti-neutrophil cytoplasmic
             antibodies) at the time of diagnosis or relapse, and at remission.

          -  Who have achieved remission using a treatment combining corticosteroids and an
             immunosuppressive agent, including corticosteroids, cyclophosphamide IV or oral (the
             use of another immunosuppressant is allowed, according to the current French
             guidelines, as well as plasma exchanges and/or IV immunoglobulins, or rituximab).

          -  Interval of 1 month between the end of the immunosuppressant treatment and the
             randomization time if cyclophosphamide or methotrexate were used, interval between 4
             and 6 months if rituximab was used

          -  Age > 18 years without age limit higher when the diagnosis is confirmed.

          -  Informed and having signed the consent form to take part in the study.

        Exclusion Criteria:

          -  Other systemic vasculitis

          -  Secondary vasculitis (following neoplastic disease or an infection in particular)

          -  Induction treatment with a regimen not corresponding to that recommended in France.

          -  Patient who has not achieved remission.

          -  Incapacity or refusal to understand or sign the informed consent form.

          -  Incapacity or refusal to adhere to treatment or perform the follow-up examinations
             required by the study. Non-compliance

          -  Allergy, documented hypersensitivity or contraindication to the study medication
             (cyclophosphamide, corticosteroids, azathioprine, rituximab)

          -  History of severe allergic or anaphylactic reactions to humanized or murine monoclonal

          -  Pregnancy, breastfeeding. Women of childbearing age must use a reliable method of
             contraception throughout the duration of immunosuppressive treatment up to 1 year
             after the last infusion of rituximab

          -  Infection by HIV, HCV or HBV

          -  Progressive, uncontrolled infection requiring a prolonged treatment (tuberculosis, HIV
             infection, etc.).

          -  Severe infection declared during the 3 months before randomization (CMV, HBV, HHV8,
             HCV, HIV, tuberculosis).

          -  Progressive cancer or malignant blood disease diagnosed during the 5 years before the
             diagnosis of vasculitis. Patients suffering from non-metastatic prostate cancer or
             those cured of a cancer or a malignant blood disorder for more than 5 years and not
             taking any antineoplastic agents for more than 5 years may be included.

          -  Participation in another clinical research protocol during the 4 weeks before

          -  Any medical or psychiatric disorder which, in the investigator's opinion, may prevent
             the administration of treatment and patient follow-up according to the protocol,
             and/or which may expose the patient to a too greater risk of an adverse effect.

          -  No social security

          -  Churg and Strauss syndrome

          -  Viral, bacterial or fungic or mycobacterial infection uncontrolled in the 4 weeks
             before the inclusion

          -  History of deep tissue infection (fasciitis, osteomyelitis, septic arthritis)in the
             first year before the inclusion

          -  History of chronic and severe or recurrent infection or history of preexisting disease
             predisposing to severe infection

          -  Severe immunodepression

          -  Administration of live vaccine in the four weeks before inclusion

          -  Severe chronic obstructive pulmonary diseases (VEMS < 50 % or dyspnea grade III)

          -  Chronic heart failure stade III and IV (NYHA)

          -  History of recent acute coronary syndrome, unrelated to vasculitis




18 Years - N/A

Accepts Healthy Volunteers



Loic Guillevin, MD, PhD, , 

Location Countries


Location Countries


Administrative Informations



Organization ID


Secondary IDs


Responsible Party


Study Sponsor

Assistance Publique - Hôpitaux de Paris

Study Sponsor

Loic Guillevin, MD, PhD, Study Chair, Cochin Hospital, Paris, France

Verification Date

February 2018